Dr. Slomovitz Discusses a Study of Everolimus/Letrozole or Hormonal Therapy in Endometrial Cancer

Brian M. Slomivitz, MD
Published: Tuesday, Mar 27, 2018


Brian M. Slomivitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.

The response rate for the combination of everolimus/letrozole was comparable to hormonal therapy, but progression-free survival (PFS) was more favorable with  everolimus/letrozole. Patients who had not received prior chemotherapy had a response rate of 53% with everoliumus/letrozole, which Slomovitz says compares favorably to results from some of the best chemotherapy trials. The PFS in these patients was over 21 months, which is much higher than what has been seen with chemotherapy, Slomovitz says.

Thus, Slomovitz says it is safe to say that this combination is worth further investigation.
 

Brian M. Slomivitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.

The response rate for the combination of everolimus/letrozole was comparable to hormonal therapy, but progression-free survival (PFS) was more favorable with  everolimus/letrozole. Patients who had not received prior chemotherapy had a response rate of 53% with everoliumus/letrozole, which Slomovitz says compares favorably to results from some of the best chemotherapy trials. The PFS in these patients was over 21 months, which is much higher than what has been seen with chemotherapy, Slomovitz says.

Thus, Slomovitz says it is safe to say that this combination is worth further investigation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x